University of Rhode Island

DigitalCommons@URI
Institute for Immunology and Informatics
Faculty Publications

Institute for Immunology and Informatics
(iCubed)

2013

Universal H1N1 influenza vaccine development
Leonard Moise
University of Rhode Island

Frances Terry
Matthew Ardito
Ryan Tassone
Howard Latimer

See next page for additional authors
Follow this and additional works at: https://digitalcommons.uri.edu/immunology_facpubs

The University of Rhode Island Faculty have made this article openly available.
Please let us know how Open Access to this research benefits you.
This is a pre-publication author manuscript of the final, published article.

Terms of Use
This article is made available under the terms and conditions applicable towards Open Access
Policy Articles, as set forth in our Terms of Use.
Citation/Publisher Attribution
Moise, L., Terry, F., Ardito, M., Tassone, R., Latimer, H., Boyle, C., Martin, W. D., & De Groot, A. S. (2013).
Universal H1N1 influenza vaccine development. Human Vaccines & Immunotherapeutics, 9(7),
1598-1607.
Available at: http://dx.doi.org/10.4161/hv.25598

This Article is brought to you for free and open access by the Institute for Immunology and Informatics (iCubed) at
DigitalCommons@URI. It has been accepted for inclusion in Institute for Immunology and Informatics Faculty
Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact
digitalcommons@etal.uri.edu.

Authors
Leonard Moise, Frances Terry, Matthew Ardito, Ryan Tassone, Howard Latimer, Christine Boyle, William D.
Martin, and Anne S. De Groot

This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/immunology_facpubs/52

Human Vaccines & Immunotherapeutics

ISSN: 2164-5515 (Print) 2164-554X (Online) Journal homepage: http://www.tandfonline.com/loi/khvi20

Universal H1N1 influenza vaccine development
Leonard Moise, Frances Terry, Matthew Ardito, Ryan Tassone, Howard
Latimer, Christine Boyle, William D. Martin & Anne S. De Groot
To cite this article: Leonard Moise, Frances Terry, Matthew Ardito, Ryan Tassone, Howard
Latimer, Christine Boyle, William D. Martin & Anne S. De Groot (2013) Universal H1N1 influenza
vaccine development, Human Vaccines & Immunotherapeutics, 9:7, 1598-1607, DOI: 10.4161/
hv.25598
To link to this article: http://dx.doi.org/10.4161/hv.25598

Copyright © 2013 Landes Bioscience

Published online: 11 Jul 2013.

Submit your article to this journal

Article views: 342

View related articles

Citing articles: 4 View citing articles

Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=khvi20
Download by: [72.215.236.254]

Date: 08 October 2015, At: 12:07

Special Focus Research Paper

Human Vaccines & Immunotherapeutics 9:7, 1598–1607; July 2013; © 2013 Landes Bioscience

Universal H1N1 influenza vaccine development
Identification of consensus class II hemagglutinin
and neuraminidase epitopes derived from strains
circulating between 1980 and 2011
EpiVax, Inc.; Providence, RI USA; 2Institute for Immunology and Informatics; University of Rhode Island; Providence, RI USA

1

Downloaded by [72.215.236.254] at 12:07 08 October 2015

Keywords: epitope, T cell, influenza, seasonal influenza, pandemic influenza, H1N1, universal influenza vaccine,
immunoinformatics, computational immunology, vaccine

Immune responses to cross-conserved T cell epitopes in novel H1N1 influenza may explain reports of diminished influenzalike illnesses and confirmed infection among older adults, in the absence of cross-reactive humoral immunity, during the
2009 pandemic. These cross-conserved epitopes may prove useful for the development of a universal H1N1 influenza
vaccine, therefore, we set out to identify and characterize cross-conserved H1N1 T cell epitopes. An immunoinformatic
analysis was conducted using all available pandemic and pre-pandemic HA-H1 and NA-N1 sequences dating back to
1980. Using an approach that balances potential for immunogenicity with conservation, we derived 13 HA and four NA
immunogenic consensus sequences (ICS) from a comprehensive analysis of 5,738 HA-H1 and 5,396 NA-N1 sequences.
These epitopes were selected because their combined epitope content is representative of greater than 84% of prepandemic and pandemic H1N1 influenza strains, their predicted immunogenicity (EpiMatrix) scores were greater than or
equal to the 95th percentile of all comparable epitopes, and they were also predicted to be presented by more than four
HLA class II archetypal alleles. We confirmed the ability of these peptides to bind in HLA binding assays and to stimulate
interferon-γ production in human peripheral blood mononuclear cell cultures. These studies support the selection of the
ICS as components of potential group-common H1N1 vaccine candidates and the application of this universal influenza
vaccine development approach to other influenza subtypes.

Introduction
Despite intense efforts at epidemiological tracking and computational modeling, the timing and severity of influenza outbreaks
remain difficult to predict, as illustrated by the last two influenza
seasons. On average, influenza-like illness (ILI) reports exceed
the Centers for Disease Control and Prevention’s (CDC) national
baseline for a period of 12 weeks. During the 2011–2012 season, there was only one week of ILI reports above baseline. In
contrast, the 2012–2013 season saw the earliest outbreak since
2003–2004, and roughly 15 weeks of ILI reports above baseline
were documented.1
Vaccination is the only public-health means for reducing the
impact of influenza morbidity and mortality by offsetting the
uncertainties of timing and virulence arising from uncontrollable
complexities of population, behavioral, viral, and environmental factors. Vaccination is also considered a cornerstone approach
for pandemic preparedness. The principle approach to influenza vaccine design focuses on raising antibodies that prevent

hemagglutination. Generally, vaccination does induce hemagglutinating antibodies but these antibodies are neither cross-reactive with other strains, nor persistent. Furthermore, vaccination
against influenza is only moderately effective. A meta-analysis
using data from randomized, controlled trials conducted over 12
seasons and published between 1967 and 2011 demonstrated that
trivalent influenza vaccination (TIV) in adults aged 18–65 years
provided only moderate protection (59%) over eight seasons and
significantly lower levels in other seasons.2 Live attenuated influenza vaccine (LAIV), which stimulates both cellular and humoral
immunity, showed higher efficacy (83%) in children aged 6 to 17
years, but not in adults. To improve on the shortcomings of existing influenza vaccination approaches, novel vaccine approaches
that aim to provide universal protection are needed.
We became interested in the concept of cross-reactive T cell
epitopes for influenza during the 2009 H1N1 pandemic. At that
time, the Centers for Disease Control and Prevention reported
that seasonal flu vaccines did not elicit cross-reactive neutralizing
antibodies against the emerging pandemic (H1N1) 2009.3 When
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Figure 1. Informatic-driven identification of influenza H1N1 hemagglutinin and neuraminidase immunogenic consensus sequences. Results
of the step-wise computational process of screening H1-HA and N1-NA
sequences for conserved and potentially immunogenic epitopes and
constructing immunogenic consensus sequences are shown.

early clinical reports released during the 2009 A(H1N1) pandemic suggested the novel influenza was more virulent among
children and adults under 65 years than the elderly, we hypothesized that cellular responses to cross-reactive T cell epitopes
might explain the unexpected disease distribution. The apparent
lack of B cell epitope conservation in novel H1N1 and absence
of cross-reactive antibodies raised by the seasonal vaccine H1N1
strain at the time supported this idea.
Thus, we set out to identify cross-conserved T cell epitopes in
the pandemic and the 2008–2009 seasonal vaccine hemagglutinin (HA) and neuraminidase (NA) antigens, as soon as the first
pandemic influenza sequences became available, using immunoinformatic methods.4 The HLA class II epitope predictions were
later confirmed experimentally using peripheral blood mononuclear cells from human donors not exposed to the pandemic
virus,5 illustrating that pre-existing CD4 + T cells elicit crossreactive effector responses against the pandemic H1N1 virus. In
addition, they demonstrated that the computational tools were
90% accurate in predicting CD4 + T cell epitopes and their HLADR-dependent response profiles in donors that were chosen at
random for HLA haplotype. As HA and NA antigens are the
principle components of seasonal trivalent inactivated and subunit influenza vaccines and CD4 + T cells support both humoral
and cellular influenza immunity, we have now performed a significantly expanded immunoinformatic analysis of the H1-HA
and N1-NA sequence space to identify HLA class II-restricted
immunogenic consensus sequences covering isolates dating back
to 1980 from the end of the 2009 pandemic. The novel antigens
were validated in HLA binding and T cell assays in preparation
for future vaccine efficacy studies in HLA transgenic mice. We
provide a detailed report on the methods used to define these
highly cross-conserved influenza vaccine epitopes. The method
may be of interest for the design of future H7N9, H5N1, and
H3N2 vaccines.
Results

Figure 2. Conservation distribution of influenza H1N1 hemagglutinin
and neuraminidase 9-mers. Pre-pandemic and pandemic H1-HA (A)
and N1-NA (B) sequences were parsed into overlapping nine amino
acid frames with a one amino acid frameshift, and unique 9-mers were
evaluated for percent coverage of source antigens at 100% sequence
identity using the Conservatrix algorithm. Inset: Close-up of the
75–100% coverage range.
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9-mer conservation and HLA binding potential. Influenza
H1N1 HA and NA sequences dating back to 1980 were computationally screened in a step-wise process to identify conserved
and potentially immunogenic epitopes (Fig. 1). A total of 5,738
influenza A H1-HA sequences were collected, comprising 4,110
(71.6%) pandemic 2009 and 1,628 (28.3%) pre-pandemic
sequences. A total of 3,200,273 9-mers were parsed from these
sequences and duplicates were removed, leaving 16,247 unique
9-mers (0.5%). Of the unique HA 9-mers, 3,396 were predicted
by EpiMatrix to bind to at least one of eight archetypal HLA
class II alleles (20.1%). One hundred and sixty-eight 9-mers were
found in more than 75% of the input HA proteins (Fig. 2A),
covering an average of 99% and 95% of pandemic and pre-pandemic sequences, respectively. A set of 5,396 influenza A N1-NA
sequences was also assembled, including 3,574 (66.2%) pandemic and 1,822 (33.8%) pre-pandemic, post-1980 sequences.
From these N1-NA sequences, 2,488,564 9-mers were parsed,
11,065 of which were classified as unique (0.4%). Of the unique
NA 9-mers, 2,147 (19.4%) were predicted to bind to at least one
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Figure 3. Immunogenic consensus sequence influenza H1N1 strain
coverage and HLA binding potential. ICS construction yielded 13 H1-HA
and four N1-NA sequences with >85% coverage of input proteins and
EpiMatrix cluster scores >10, representing significant HLA binding potential. Bars represent EpiMatrix cluster score and open circles percent
strain coverage.

receptor-facing pattern with predicted mouse MHC-binding
sequences, despite H1-1 and N1-1 containing 9-mers with seven
out of nine identities. Potential cross-reactivity between H1-7,
H1-9, N1-1, and N1-4 ICS and human commensal sequences was
also considered to be negligible, using JanusMatrix. In contrast,
a screen of non-influenza pathogens uncovered multiple 9-mers
with 7 out of 9 identities, although few were well matched by
HLA allele and TCR-facing side chains. The “other pathogen”
that matched most often to ICS peptides was Salmonella Typhi,
with similar sequences observed in H1-2, -3, -4, -5, -8, and -13.
Notably, in a screen of H5N1 influenza HA and NA sequences,
five HA and four NA ICS were found to be homologous. This
suggests that this methodology has identified influenza sequences
that are both highly conserved and potentially immunogenic,
enhancing their utility as universal influenza vaccine candidate
epitopes.
HLA binding. ICS peptides were assayed in vitro for their
capacity to bind multiple HLA types, including DRB1*0101,
DRB1*0301, DRB1*0401, DRB1*0701, DRB1*1101, and
DRB1*1501. Of the 108 ICS peptide-HLA binding interactions
assayed, 3% bound with very high affinity, 23% bound with
high affinity, 26% bound with moderate affinity, 30% bound
with low affinity, 2% with very low affinity, and 15% had no
affinity for the HLA tested (Fig. 4).
All (100%) of the peptides bound as predicted to at least three
HLA alleles, 89% to at least four HLA alleles, 72% to at least five,
and 39% to all six. A non-binder was defined as a confirmed prediction (true negative) if the peptide had an EpiMatrix Z-score
that was lower than the defined cut-off (1.64) for its associated
HLA allele. Positive predictions were defined as epitopes scoring
≥ 1.64 on the EpiMatrix Z-scale and binding HLA at any affinity.
The concordance of computational predictions and binding assay
results was evaluated with classification of peptide-HLA binding
pairs as either true positive, false positive, true negative, or false
negative. Overall, the concordance with predictions (both positive and negative) was 83%. With respect to each allele assayed,
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HLA class II allele. One hundred and twenty-two 9-mers were
found in more than 75% of the input NA proteins (Fig. 2B),
covering 99% of pandemic and 96% of pre-pandemic sequences.
Interestingly, a second cluster of “high-range” conserved
9-mers was observed in the conservation distribution of both protein sets (Fig. 2). Three hundred 87 HA 9-mers (2.3%) and 339
NA 9-mers (3.1%) were found in 50–74% of input sequences.
These sequences may represent regions that tolerate limited variability on the level observed in antigenic shifts. The remaining
15,692 HA (96.5%) and 10,604 NA peptides (95.8%) were
found in < 50% of input sequences with 14,671 HA and 9,744
NA peptides conserved in < 1% of unique 9-mers, as is expected
for these highly variable antigens.
ICS construction and selection. Drawing from the set of
9-mer sequences with >75% conservation, a total of 19 immunogenic consensus sequences (ICS) derived from HA and eight ICS
from NA were constructed by the EpiAssembler algorithm. This
algorithm has been used to identify consensus sequences from
highly variable proteins that are balanced for immunogenicity
and conservation.6,7 One drawback to the approach is that given
the large sampling of protein isolates, identifying multiple similar, though not identical, 9-mers that derive from the same region
of HA or NA and retain significant HLA binding potential is
highly likely. Indeed, 6 ICS from the HA set were eliminated due
to redundant core peptide sequences. In this case, we selected the
sequence that had the highest conservation from the set of redundant sequences. A final set of 13 HA and four NA ICS epitopes
was retained based on the previously defined characteristics: high
influenza strain coverage (>85% conservation among input proteins), excellent immunogenicity scores (EpiMatrix cluster scores
> 10), and promiscuous HLA binding potential (Fig. 3; Table 1).
All HA and NA ICS are homologous to published HLA ligands
and/or HLA DR-restricted T cell epitopes, according to a BLAST
screen of the Immune Epitope Database at 90% coverage.8
By sequence comparison, we evaluated the potential for the
selected H1N1 ICS to trigger immune responses from pre-existing T cells that bear TCR specific for epitopes contained in host
or commensal antigens. We normally eliminate any such crossreactive epitopes because activation of T cells cross-reactive with
self or with commensals in the context of immunization may lead
to unexpected immune responses that limit efficacy. For example,
activation of cross-reactive host-specific natural regulatory T cell
activation may dampen vaccine responses. Alternatively, T cells
that express T cell receptors (TCRs) trained on commensal antigens may lead to induction of cross-reactive T cells with effector
phenotypes, an event that may perturb immune homeostasis. By
BLAST analysis, no homology between influenza and human
sequences was identified in any of the final 17 ICS selections.
Even though 12 ICS were observed to be homologous to murine,
commensal, and other pathogen (non-influenza) sequences, they
were not eliminated from the final set selected for experimental
validation. None of these ICS bear TCR-facing sequences that
are fully conserved with their murine and commensal homologs
and preserve MHC binding potential, suggesting a low probability for cross-reactivity. Using a new tool that evaluates TCR
facing residues, JanusMatrix,9 we found no ICS shares a T cell

Table 1. H1N1 immunogenic consensus sequences
A
% Coverage
All H1N1
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#

HA
POS

N
TERM

CORE PEPTIDE

C
TERM

# Hits

CLUSTER
SCORE

#
EpiBars

2273
Unique
Sequences

IEDB

Pandemic
H1N1

PrePandemic
H1N1

1410 Unique
Sequences

870
Unique
Sequences

1

112

FIQ

YEELREQLSSVS

AFE

9

14.78

1

98.7%

98.7%

97.0%

2

440

AEM

LVLLENERTLDY

YDS

10

16.02

1

99.2%

98.9%

99.2%

3

523

ESA

RIYQILAIYSTVAS

TLV

15

25.59

3

99.6%

99.0%

99.2%

4

396

VNS

IIEKMNTQFTAVG

KEF

8

11.07

1

98.9%

98.4%

99.2%

HLA
Binding

T Cell
Assay

Y
Y

Y
Y

Y

Y

5

527

IYQ

ILVIYSTVASSLVL

SVS

20

35.15

4

98.6%

98.1%

99.2%

Y

6

463

YEK

VRSQLKNNAKEIG

NGC

12

22.54

2

99.0%

96.3%

98.5%

Y

7

548

GAV

SFWMCSNGSLQ

FRI

7

11.78

1

97.4%

95.8%

99.7%

8

432

FMD

IWTYNAELLVLL

DNE

7

10.15

1

99.7%

99.3%

100.0%

9

38

ERN

VTVTHSVNLLE

EKH

8

13.13

1

95.1%

92.4%

99.0%

Y

10

19

TLS

IGYHANNSTDT

EDT

6

10.35

1

99.7%

99.6%

99.5%

Y

11

326

STR

LRMVTGLRNVPSIQS

KGL

17

28.36

3

93.3%

92.0%

93.3%

13

386

QNA

INRITNKVNSVI

KKM

8

11.54

2

96.8%

98.2%

94.5%

19

337

NVP

FIQSRGLFGAIAGFI

EGG

12

19.73

2

99.5%

99.2%

99.1%

Y
Y

Y

Y

Y
Y

Y

Y

B
Neuraminidase Immunogenic Consensus Sequences

NA
POS

N
TERM

CORE PEPTIDE

1

129

CRN

FFLTQGALLN

#

% Coverage

C
TERM

# Hits

CLUSTER
SCORE

#
EpiBars

DRH

12

23.64

2

IEDB

All H1N1

Pandemic
H1N1

PrePandemic
H1N1

2273
Unique
Sequences

1410 Unique
Sequences

870
Unique
Sequences

98.4%

99.1%

97.8%

HLA
Binding

T Cell
Assay

Y

2

79

SVL

SVKLAGNSSLCS

TSG

12

22.78

2

89.2%

92.1%

82.8%

3

17

IIG

LILQIGNIISI

WPV

14

27.31

2

93.2%

96.6%

89.7%

Y

4

439

SGS

IISFCGVNSDTV

DWS

7

11.19

1

80.6%

95.4%

65.5%

Y

Y

Y

Key features of HA and NA ICS produced by the EpiAssembler algorithm are presented, including position in the native antigen sequence relative to
Influenza A/California/04/2009 (HA/NA POS), N- and C-terminal flanking residues (NTERM/CTERM), core immunogenic peptide sequence (CORE PEPTIDE),
EpiMatrix 9-mer-to-HLA-allele hits (#HITS), overall peptide promiscuous binding potential where ≥ 10 is significant (CLUSTER SCORE), number of 9-mers
with promiscuous binding potential where ≥ 1 is significant (#EpiBars). Peptides previously shown to bind HLA-DR (IEDB: HLA Binding) or to stimulate
HLA-DR-restricted T cell responses (IEDB: T Cell Assays) as reported in the Immune Epitope Database are noted. Conservation is summarized by classification (Pandemic vs. Pre-Pandemic) and overall. % Coverage describes how many of the individual protein isolates are represented with at least one of the
HLA-binding 9-mers in an ICS.

the values are 88% for DRB1*0101, 76% for DRB1*0301, 88%
for DRB1*0401, 78% for DRB1*0701, 82% for DRB1*1101, and
82% for DRB1*1501. These HLA-binding and epitope prediction results are consistent with previously published studies using
the same algorithms and assay conditions.10,11
Discrepancies between computational predictions and
experimental results are expected, in part, because immunoinformatic algorithms are not 100% accurate. A recent retrospective evaluation of epitope mapping algorithm accuracy showed
EpiMatrix was > 75% accurate across all the HLA class II alleles
studied here.12 In comparison with other major prediction tools,
EpiMatrix compared favorably, with equal or greater accuracy

www.landesbioscience.com

both overall and for individual alleles. Additionally, prediction/
experimental discrepancies are introduced in binding assays by
epitope-specific factors, including peptide design and the unique
physical and chemical properties of individual peptides that, for
example, may contribute to aggregation.
T cell reactivity. To further support the choice of these immunogenic consensus sequences as potential vaccine candidates, we
stimulated human peripheral blood mononuclear cells (PBMCs)
with ICS peptides and measured cytokine production to demonstrate that the peptides are immunoreactive. While HLA binding assays establish that a sequence can be presented to T cells,
cytokine measurements demonstrate epitope antigenicity. Over a
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Discussion
Cross-reactive T cell epitopes such as the ones identified here may
have played a significant role in containing the human impact
of the 2009 influenza H1N1 pandemic. Despite studies showing pandemic H1N1 was highly pathogenic in laboratory animals and shared few B cell epitopes with most seasonal H1N1
viruses,13 the virus triggered only mild symptoms in middle-aged
and elderly adults and, fortunately, failed to cause widespread

1602

Figure 4. ICS peptide – HLA DR binding affinities. Peptide identifiers
and sequences are noted in the first and second columns, respectively.
IC50 values in μM units were calculated from curves fitted to dosedependence competition binding data for each peptide-HLA DR allele
pair. Peptide binding affinity is shown according to the following classification: IC50 < 0.1 μM (black), 0.1 μM < IC50 < 1 μM (dark gray),
1 μM < IC50 < 10 μM (gray), 10 μM < IC50 < 100 μM (light gray), IC50 >
100 μM (lightest gray). IC50 values too high to accurately measure under
binding conditions tested are considered non-binders (NB; shown in
white cells).

morbidity and mortality.14 One explanation for this unexpected
observation is that pre-existing influenza-specific CD4 + T cells
generated cross-reactive responses against the virus that were
capable of limiting disease severity and virus spread in individuals lacking cross-protective humoral immunity. This hypothesis
is supported by a number of in vitro and in vivo studies: independent studies demonstrated cytotoxic T lymphocytes (CTLs)
and CD4 + T cells raised against the seasonal H1N1 viruses, A/
Brisbane/59/2007 and A/New Caledonia/20/99, respectively,
were capable of responding against whole protein antigens from
the pH1N1 virus.5,15-17 In mice and in humans, memory T cells
to conserved epitopes have been shown to confer protection to
heterotypic infection.18,19 In addition, cross-reactive human T
helper cell responses were observed for HLA-DR4 epitopes.20
Moreover, ferrets infected with seasonal H1N1 influenza, though
lacking sterilizing immunity, were protected from disease upon
subsequent pH1N1 infection.21 During the pandemic, a lower
hospitalization rate and lower reports of H1N1 infection among
recent seasonal vaccinees was observed in a case-control study
in Mexico.22 And finally, a T cell-driven influenza vaccine was
recently shown to be protective against influenza challenge in
human studies.23 Taken together, these studies support the usefulness of including influenza antigens that can elicit cross-strain
T helper cell responses in a universal influenza vaccine.
The activation of helper T cells is also critically important to
the magnitude, quality, and kinetics of antibody response.24 In
the absence of functional (memory) CD4 + T cells, mouse studies have shown that the rate of viral clearance upon secondary
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nine-day period, we expanded antigen-specific T cells from five
young adult subjects, with unknown influenza infection and vaccination history, by stimulation with a pool of HA and NA ICS
peptides. Cells were then re-stimulated with pooled or individual
ICS peptides for measurement of interferon-γ (IFNγ) production by ELISpot assay. Cultured ELISpot assays were performed
because ex vivo responses were not robust, suggesting that antigen-specific T cell precursor frequencies were too low to observe
without amplification (data not shown). Cultured ELISpot
responses were significantly greater than ex vivo responses and
were considered positive when (1) the number of IFNγ spotforming cells exceeded 50 per million PBMCs cultured, (2)
spot counts were at least twice background, and (3) spot counts
were statistically different from “no stimulus” measurements
(p < 0.05). All subjects responded to the pool of ICS peptides
(Fig. 5; Table 2). Apart from Subject 844, all pooled peptide
re-stimulations elicited robust numbers of IFNγ-producing cells,
ranging from 1127 to 4737 per million PBMCs with stimulation
index values at least three times the cutoff value of two. It is possible Subject 844 did not respond strongly to the ICS peptides
because of no prior history of H1N1 exposure or vaccination.
These data show that H1N1 cross-reactive memory T cell precursors do exist and have the potential to be substantially expanded
by vaccination with universal H1N1 antigens.
Individual ICS peptides stimulated significant IFNγ production in all subjects but Subject 844 (Table 2). Excluding this
subject, positive responses per subject ranged from 24% to 65%
over all 17 ICS peptides. By source antigen, positive responses
ranging from 31% to 69% per subject were observed for the 13
HA ICS peptides and 0% to 50% for the four NA ICS peptides.
Thirteen out of the 17 ICS peptides (76%) stimulated positive
responses in at least one subject. By source antigen, 10 out of 13
HA ICS (77%) and 3 out of 4 NA ICS (75%) peptides were positives. Two ICS peptides, HA-3 and HA-8, were immunoreactive
in all cases except Subject 844, suggesting that T cells specific for
these sequences may be immunodominant. Unexpectedly, four
ICS peptides stimulated no responses in any subjects. The small
cohort size of the study with limited HLA diversity may explain
this result. Alternatively, these sequences may stimulate type 1
helper T cell cytokines other than IFNγ, such as interleukin-2
and tumor necrosis α. Additionally, vaccination may increase the
numbers of precursor cells to the level needed for detection by
cultured ELISpot. Thus, positive responses may be observed in
a larger cohort with broader HLA coverage, comparing multiple
cytokine responses in samples drawn before and after vaccination. Future studies will address these factors.

infection slows considerably, beyond the degree seen in the primary response.25-27 Also in mice, cross-reactive memory T helper
cells have been shown to contribute to cross-strain antibody
responses.28 In human populations, cross-reactive T cell responses
have been observed between circulating strains of influenza and
epidemic strains (such as H5N1) in the absence of cross-reactive
antibodies.29 Both cross-reactive CTLs and T helper cells have
been identified by a number of investigators.30,31 T cell responses
to conserved epitopes may be particularly important when new
strains of influenza emerge.

www.landesbioscience.com
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Figure 5. Antigen-specific human IFNγ ELISpot responses to computationally identified influenza HA and NA immunogenic consensus
sequences. ICS were assayed for T cell reactivity by IFNγ ELISpot assay
using PBMCs isolated from normal human donors (n = 5). An ELISpot
response was considered positive if three criteria were met: (1) spotforming cells (SFC) per million PBMC were at least 50 over background;
(2) SFC per million PBMC were at least 2-fold over background; and (3)
antigen-stimulated SFC numbers were statistically different (p < 0.05)
from non-stimulated counts. (A) The numbers of SFC over background
per million PBMCs that secrete IFNγ in response to individual and
pooled influenza HA and NA ICS are presented. Individual subject
responses are represented by dots and the average response across
subjects by horizontal lines. The 50 SFC over background per million
PBMCs cutoff is denoted by the dotted line. (B) The ELISpot response
stimulation index, representing the ratio of antigen-stimulated SFC
counts to non-stimulated counts, is presented. Stimulation index values
per individual subject are represented by dots and the average values
across subjects by horizontal lines.

The comprehensive approach to defining highly conserved
H1N1 sequences described here builds on our initial analysis and
identification of cross-conserved H1-HA and N1-NA T-cell epitopes that was published during the 2009 influenza A(H1N1)
pandemic. A comparison of the results from these two independent analyses shows that the wider net cast for H1N1 sequences
in the present study yielded a set of sequences, some of which
are similar and some different from the original screen. Nine of
13 ICS derived from this collection of HA antigens and three
of four NA ICS newly derived in the present work are similar to
those identified in the initial analysis. Additionally, we previously
identified three cross-conserved immunogenic sequences from
each antigen, which were not sufficiently conserved in the larger
sequence data set to be represented in the final selections made
here. This comprehensive set of more highly conserved H1N1
sequences will be further tested in in vivo studies with HLA
transgenic mice, before moving them forward into formulation
studies for vaccine development purposes.
We used HLA binding as a proxy for immunogenicity,
although binding is not an absolute indicator of immunogenicity potential. The results showed that the ICS peptides are
promiscuous binders, suggesting they may be broadly immunoreactive. As well, they showed that the immunoinformatic predictions were highly (83%) accurate. Furthermore, in vitro T cell
responses to 76% of the individual ICS peptides were observed
in a small cohort of healthy subjects. In addition, the results confirmed epitopes that have been previously published, based on
a search of the IEDB. While our report focuses on HLA class
II-restricted CD4 + T helper epitopes, CTLs are also required for
viral clearance, some of which may be CD4 +.32 Taken together,
the combination of epitope prediction and HLA binding and
immunoreactivity data here shows that these cross-conserved
influenza sequences have promiscuous HLA binding and antigenicity properties required to identify broadly reactive, crossprotective H1N1 influenza-specific T cells raised in infection or
vaccination and to serve as immunogens in a universal H1N1
influenza vaccine.
The level of conservation of these sequences among H1N1
sequences extending from 1980 to 2011 is quite remarkable and
illustrates the capacity of epitope-mapping tools to discover highvalue sequences for vaccine design. The immunoinformatics
approach described here allows for the identification and characterization of cross-conserved T cell epitopes for any set of source
sequences. Notably, this universal influenza vaccine development
approach may be applied to other influenza subtypes (H7, H5,
for example). We have also developed tools that identify highly
cross-conserved CD8 + T cell responses and have validated their
accuracy.33-35 Highly efficient algorithms, such as these, may be
useful for accelerated development of vaccines against emerging
infections in the context of newly emerging infections or bioterror events.36
An important safety feature of the vaccine design approach
described here is that T cell epitopes that have a high degree of
cross-conservation with human genome are taken into consideration and eliminated from the list of epitopes to be tested and
included in vaccine constructs, as there is at least initial evidence
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844 (DR1, DR4)

1489 (DR1, DR4)

1003 (DR4, DR4)

720 (DR1, DR7)

1442 (DR4, DR13)

SFC

SI

p-value

SFC

SI

p-value

SFC

SI

p-value

SFC

SI

p-value

SFC

SI

p-value

%
Subjects
Positive

HA-1

143

1.30

0.346

267

1.23

0.129

397

5.17

< 0.001

293

11.00

0.001

507

0.85

0.217

40%

HA-2

137

1.24

0.506

207

0.95

0.741

177

2.30

0.002

310

11.63

< 0.001

540

0.91

0.327

40%

HA-3

117

1.06

0.863

603

2.78

< 0.001

1180

15.39

< 0.001

280

10.50

< 0.001

2297

3.87

< 0.001

80%

HA-4

137

1.24

0.529

610

2.82

0.005

1000

13.04

< 0.001

587

22.00

< 0.001

1023

1.72

< 0.001

60%

HA-5

97

0.88

0.711

170

0.78

0.171

70

0.91

0.733

103

3.88

< 0.001

480

0.81

0.042

20%

HA-6

120

1.09

0.797

120

0.55

0.035

30

0.39

0.036

13

0.50

0.121

687

1.16

0.116

0%

HA-7

150

1.36

0.301

163

0.75

0.143

107

1.39

0.142

57

2.13

0.184

760

1.28

0.029

0%

HA-8

153

1.39

0.231

810

3.74

< 0.001

1217

15.87

< 0.001

163

6.13

0.034

1277

2.15

< 0.001

80%

HA-9

133

1.21

0.521

210

0.97

0.856

160

2.09

0.003

43

1.63

0.063

530

0.89

0.365

20%

HA-10

190

1.73

0.081

263

1.22

0.301

147

1.91

0.008

53

2.00

0.032

513

0.87

0.185

20%

HA-11

203

1.85

0.080

820

3.78

< 0.001

837

10.91

< 0.001

177

6.63

0.001

777

1.31

0.034

60%

HA-13

110

1.00

1.000

190

0.88

0.529

97

1.26

0.316

50

1.88

0.036

497

0.84

0.071

0%

HA-19

83

0.76

0.477

170

0.78

0.154

3763

49.09

< 0.001

73

2.75

0.028

3643

6.14

< 0.001

60%

NA-1

140

1.27

0.390

200

0.92

0.580

127

1.65

0.147

143

5.38

0.009

630

1.06

0.470

20%

NA-2

143

1.30

0.346

230

1.06

0.740

270

3.52

< 0.001

117

4.38

< 0.001

517

0.87

0.226

40%

NA-3

147

1.33

0.318

260

1.20

0.279

200

2.61

0.006

33

1.25

0.553

537

0.90

0.494

20%

NA-4

150

1.36

0.270

210

0.97

0.873

103

1.35

0.385

27

1.00

1.000

580

0.98

0.795

0%

ICS
Pool

223

2.03

0.026

2457

11.34

< 0.001

4813

62.78

< 0.001

1153

43.25

< 0.001

3971

6.69

< 0.001

100%

Immunoreactivity data for influenza H1N1 ICS peptides are presented from cultured IFNγ ELISpot assays performed for five human subjects. An ELISpot
response was considered positive if three criteria were met: (1) spot-forming cells (SFC) per million PBMC were at least 50, (2) SFC per million PBMC
were at least 2-fold over background, and (3) SFC per million PBMC were statistically different from “no stimulus” measurements by the Student’s t-test
(p < 0.05). Results that meet individual criteria are highlighted in gray. Results that meet all three criteria are denoted in bold. Column headers: human
subject ID code and HLA class II type in parentheses; numbers of spot forming cells per million PBMCs that secrete IFNγ in response to individual and
pooled ICS peptides (SFC); stimulation indices (SI); and Student’s t-test results (p-value); and percent of subjects responding. Row labels: peptide ID.
Epitopes are grouped according to their source antigen, either HA or NA. It is possible Subject 844 did not respond strongly to the ICS peptides because of no prior history of H1N1 exposure or vaccination.

that such epitopes may be immunopathogenic (refs. 9, 37, 38 and
Losikoff P et al., in preparation), or tolerated by the immune system, or they may stimulate regulatory T cell responses.9
Accumulating evidence suggests that the sequences identified here may stimulate influenza-specific T helper cells that can
limit disease through activation of cellular and humoral immune
mechanisms reported to be critical for immunity. Not only do
CD4 + T cells play a role in the rate of viral clearance,25 but memory
helper T cells specific to a previous influenza strain contribute to
distinct cross-strain antibody responses.28 Thus, influenza vaccine
strategies that focus the T cell response on cross-reactive sequences
may harness cellular and humoral mechanisms with the potential
to provide group-common protection against disease.
Materials and Methods
Immunoinformatics. Sequence collection. Hemagglutinin and
neuraminidase sequences were obtained from the NIAID
Influenza Research Database (http://www.fludb.org).39 H1N1
HA and NA sequences isolated from human hosts and deposited between January 1980 and June 2011 were downloaded and
annotated by origin. Swine origin viral isolates were designated

1604

“Pandemic,” whereas all other isolates were designated “nonPandemic H1N1,” according to the SOP for New Pandemic
(H1N1)
Classification
(http://www.fludb.org/brcDocs/
documents/2009H1N1vSOP.pdf).
Conservation analysis. Because the HLA binding groove
accepts 9-mer peptides, input HA and NA sequences were parsed
into overlapping 9-mer frames, irrespective of protein alignment,
using the Conservatrix algorithm. All resulting 9-mers were
ranked by their conservation within each antigen set.
EpiMatrix analysis. All unique 9-mers resulting from
Conservatrix analysis were scored for binding potential against
a panel of eight representative class II HLA alleles using the
EpiMatrix algorithm.40 The peptide-binding preferences of these
alleles, HLA DRB1*0101, *0301, *0401, *0701, *0801, *1101,
*1301 and *1501, are expected to cover over 95% of human populations worldwide.41 EpiMatrix scores for each allele are normalized on a Z-scale; peptides scoring > 1.64 are called “hits.” These
sequences represent the top 5% of any normally distributed set
of 9-mer peptides and are highly likely to be true HLA ligands.
Construction of immunogenic consensus sequences. The
EpiAssembler algorithm was employed to create immunogenic consensus sequences (ICS) using data collected during
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Table 2. Cultured human IFNγ ELISpot responses to influenza H1N1 ICS peptides
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multiple HLA alleles. A competition-based HLA binding format
was adapted from Steere et al.45 Briefly, in racks of 1.1 ml tubes,
non-biotinylated test peptides over a wide range of concentrations competed for binding to soluble class II molecules (2.5 nM)
against a biotinylated standard peptide at a fixed concentration (25 nM) at 37°C for 24 h to reach equilibrium. Class II
molecules were then captured on ELISA plates using pan antiClass II antibodies (L243, anti-HLA-DR). Plates were washed
and incubated with Europium-labeled streptavidin for one hour
at room temperature. Europium activation buffer was added to
develop the plates for 15–20 min at room temperature before
they were read on a Time Resolved Fluorescence (TRF) plate
reader. All assays were performed in triplicate. Dose dependence
curves were generated by fitting data using the four-parameter
logistic equation, and IC50 values were calculated in SigmaPlot
11.0 (Systat, Chicago, IL). Based on the IC50 values, peptide
binding to a given HLA allele was classified as very high affinity
(< 100 nM), high affinity (100–1,000 nM), moderate affinity
(1000–10,000 nM), low affinity (10,000–100,000 nM), or very
low affinity (> 100,000 nM). Peptides that did not inhibit the
binding of the biotinylated reference peptide at any concentration
were considered non-binders. Binding assays were performed for
six alleles: DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701,
DRB1*1101 and DRB1*1501, providing a broad representation of
class II HLA allele binding pockets.41
PBMC collection and characterization. Frozen PBMCs
donated by five healthy adults, ages 18 to 65 y, were generously
provided by VaxDesign. No information on influenza vaccination or exposure was provided. Donor HLA class II types
were determined using the One Lambda Micro SSPTM High
Resolution HLA class II kit at the Hartford Hospital Transplant
Immunology Laboratory. Human subject studies were performed
in accordance with NIH regulations and with the approval of
the Ethical and Independent Review Services institutional review
board.
PBMC culture. Thawed whole PBMC populations were
rested overnight and then expanded by antigen stimulation over
nine days at 37°C under a 5% CO2 atmosphere. In a 48-well
plate, 5 × 106 cells in 150 μl Iscove’s Modified Dulbecco’s
Medium (IMDM) were stimulated with a pool of HA and NA
ICS peptides at 10 μg/ml on Day 1. Three days later, IL-2 was
added to 10 ng/ml and the culture volume raised to 300 μl. On
Day 7, cells were supplemented with 10 ng/ml IL-2 by half media
replacement. Finally, two days later, PBMCs were collected and
washed in preparation for antigen re-stimulation to measure
cytokine secretion measurements by enzyme-linked immunospot
(ELISpot) assay.
ELISpot assay. Interferon-gamma (IFNγ) ELISpot assays
were performed using kits purchased from Mabtech and performed according to the manufacturer’s specifications. Target
peptides were added individually at 10 μg/ml and pooled at 1.25
μg/ml to triplicate wells containing 100,000 PBMCs in IMDM
supplemented with 10% human AB serum. Cells were incubated
for 48 h at 37°C under a 5% CO2 atmosphere. Triplicate wells
were plated with PHA (10 μg/ml) as a positive control, and six
wells with no peptide were used for background determination.
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conservation analysis and EpiMatrix analysis.7 ICS are class II
epitope-length peptides of 20–25 residues each, whose composition has been enriched for both HLA binding potential and
pathogen strain coverage using 9-mers from multiple isolates
aligned by position in their native protein sequence. By definition,
an ICS is seeded with a core 9-mer, and overlapping regions are
subsequently screened for high-scoring, highly conserved 9-mer
candidates to append until the optimal peptide length is reached.
The resulting ICS peptides are compact clusters of putative T cell
epitopes, each offering the advantage of targeting multiple strains
and widely variable individual hosts using a single sequence. A
conservation threshold was set such that the constituent 9-mer
frames of each resulting ICS were required, in aggregate, to cover
a minimum of 75% of input protein sequences.
Homology analysis. To eliminate peptide candidates unlikely
to stimulate effector T cell responses, H1N1 ICS sequences were
screened for homology against a set of host and commensal protein databases using the BLAST algorithm and parameters established as standards for short (peptide-length) sequences. Given that
viral epitopes may stimulate regulatory T cell responses, ICS were
screened against the complete human genome and the complete
murine genome. Sequences were also screened against human
commensals cataloged as part of the Human Microbiome Project
(www.hmpdacc.org/resources/data_browser.php),42 as well as
the larger GenBank non-redundant protein database—excluding
influenza—to identify homologous sequences in other pathogens.
Standards have been established for the annotation and finishing
of microbial genome sequences.43,44 All genomes at Finishing Level
3 (High Quality Draft) and above as of April 2011 were used to
construct a local database of human microbiome sequences against
which to screen H1N1 peptides. Finally, to establish whether any
H1N1 ICS might stimulate cross-reactive T cell responses in other
potential pandemic influenza outbreaks, peptides were screened
against all H5N1 sequences isolated from humans and available
at the GISAID database for influenza sequence sharing (http://
platform.gisaid.org) as of June 2011. As a general practice, any ICS
sharing more than seven amino acid identities per 9-mer frame was
tagged; results of homology analysis against these five databases
were reviewed on a case-by-case basis.
ICS selection. ICS peptides were manually reviewed to eliminate redundancy of core sequences due to similar, though not
identical, motifs across isolates. Ambiguity due to sequences containing unidentifiable residues at certain positions was corrected.
ICS with significant homology to host genomes were excluded,
whereas sequence similarity to other organisms would not necessarily remove a peptide from the list of candidates. In one case, a
highly hydrophobic ICS was hand modified by adding charged
residues to the N-terminal flank of the peptide to increase the
probability of successful peptide synthesis.
Peptide synthesis. Synthetic peptides were manufactured
using 9-fluoronylmethoxycarbonyl (Fmoc) chemistry by 21st
Century Biochemicals (Marlboro, MA). Peptide purity was >
80% as ascertained by analytical reversed phase HPLC. Peptide
mass was confirmed by tandem mass spectrometry.
HLA binding assay. Class II HLA binding assays were performed to screen predicted epitope sequences for binding to

Disclosure of Potential Conflicts of Interest

Two of the contributing authors, A.S.DG. and W.D.M., are
senior officers and majority shareholders at EpiVax, Inc., a
References

Downloaded by [72.215.236.254] at 12:07 08 October 2015

1.

Centers for Disease Control and Prevention. 20122013 Influenza Season Week 25 ending June 8, 2013.
Centers for Disease Control and Prevention. Retrieved
from: http://www.cdc.gov/flu/weekly/.
2. Osterholm MT, Kelley NS, Sommer A, Belongia EA.
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. [Erratum in: Lancet
Infect Dis 2012; 12:655; PMID:22032844; http://
dx.doi.org/10.1016/S1473-3099] [11] [70295-X].
Lancet Infect Dis 2012; 12:36-44; PMID:22032844;
http://dx.doi.org/10.1016/S1473-3099(11)70295-X
3. Centers for Disease Control and Prevention (CDC).
Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal
influenza vaccine. MMWR Morb Mortal Wkly Rep
2009; 58:521-4; PMID:19478718
4. De Groot AS, Ardito M, McClaine EM, Moise L,
Martin WD. Immunoinformatic comparison of T-cell
epitopes contained in novel swine-origin influenza A
(H1N1) virus with epitopes in 2008-2009 conventional influenza vaccine. Vaccine 2009; 27:5740-7;
PMID:19660593; http://dx.doi.org/10.1016/j.vaccine.2009.07.040
5. Schanen BC, De Groot AS, Moise L, Ardito M,
McClaine E, Martin W, et al. Coupling sensitive in vitro
and in silico techniques to assess cross-reactive CD4(+)
T cells against the swine-origin H1N1 influenza virus.
Vaccine 2011; 29:3299-309; PMID:21349362; http://
dx.doi.org/10.1016/j.vaccine.2011.02.019
6. Koita OA, Dabitao D, Mahamadou I, Tall M, Dao
S, Tounkara A, et al. Confirmation of immunogenic
consensus sequence HIV-1 T-cell epitopes in Bamako,
Mali and Providence, Rhode Island. Hum Vaccin 2006;
2:119-28; PMID:17012903
7. De Groot AS, Bishop EA, Khan B, Lally M, Marcon L,
Franco J, et al. Engineering immunogenic consensus T
helper epitopes for a cross-clade HIV vaccine. Methods
2004; 34:476-87; PMID:15542374; http://dx.doi.
org/10.1016/j.ymeth.2004.06.003
8. Vita R, Zarebski L, Greenbaum JA, Emami H, Hoof
I, Salimi N, et al. The immune epitope database 2.0.
Nucleic Acids Res 2010; 38(Database issue):D854-62;
PMID:19906713; http://dx.doi.org/10.1093/nar/
gkp1004
9. Moise L, Gutierrez AH, Bailey-Kellogg C, Terry F,
Leng Q, Abdel Hady KM, et al. The two-faced T cell
epitope: Examining the host-microbe interface with
JanusMatrix. Hum Vaccin Immunother 2013; 9: In
press; PMID:23584251; http://dx.doi.org/10.4161/
hv.24615.
10. De Groot AS, Ardito M, Moise L, Gustafson EA, Spero
D, Tejada G, et al. Immunogenic consensus sequence
T helper epitopes for a pan-Burkholderia biodefense
vaccine. Immunome Res 2011; 7:7; PMID:22130150

1606

privately owned biotechnology company located in Providence,
RI. L.M. is employed by and holds stock options in EpiVax.
These authors acknowledge that there is a potential conflict
of interest related to their relationship with EpiVax and attest
that the work contained in this research report is free of any
bias that might be associated with the commercial goals of
the company.
Acknowledgments

We are grateful to Dr Donald Drake (VaxDesign) for providing PBMC samples and to Lauren Levitz for a thorough reading of the manuscript. This work was supported by NIH grant
R21AI090359 (ADG).

11. Moise L, McMurry JA, Pappo J, Lee DS, Moss SF,
Martin WD, et al. Identification of genome-derived
vaccine candidates conserved between human and
mouse-adapted strains of H. pylori. Hum Vaccin
2008; 4:219-23; PMID:18376134; http://dx.doi.
org/10.4161/hv.4.3.5394
12. De Groot AS, Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic
protein therapeutics. Clin Immunol 2009; 131:189201; PMID:19269256; http://dx.doi.org/10.1016/j.
clim.2009.01.009
13. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN,
Sun H, et al. Cross-reactive antibody responses to the
2009 pandemic H1N1 influenza virus. N Engl J Med
2009; 361:1945-52; PMID:19745214; http://dx.doi.
org/10.1056/NEJMoa0906453
14. Jain S, Kamimoto L, Bramley AM, Schmitz AM,
Benoit SR, Louie J, et al.; 2009 Pandemic Influenza
A (H1N1) Virus Hospitalizations Investigation Team.
Hospitalized patients with 2009 H1N1 influenza in
the United States, April-June 2009. N Engl J Med
2009; 361:1935-44; PMID:19815859; http://dx.doi.
org/10.1056/NEJMoa0906695
15. Greenbaum JA, Kotturi MF, Kim Y, Oseroff C,
Vaughan K, Salimi N, et al. Pre-existing immunity
against swine-origin H1N1 influenza viruses in the
general human population. Proc Natl Acad Sci U S A
2009; 106:20365-70; PMID:19918065; http://dx.doi.
org/10.1073/pnas.0911580106
16. Richards KA, Topham D, Chaves FA, Sant AJ. Cutting
edge: CD4 T cells generated from encounter with
seasonal influenza viruses and vaccines have broad
protein specificity and can directly recognize naturally generated epitopes derived from the live pandemic H1N1 virus. J Immunol 2010; 185:4998-5002;
PMID:20889549; http://dx.doi.org/10.4049/jimmunol.1001395
17. Tu W, Mao H, Zheng J, Liu Y, Chiu SS, Qin G, et
al. Cytotoxic T lymphocytes established by seasonal
human influenza cross-react against 2009 pandemic H1N1 influenza virus. J Virol 2010; 84:652735; PMID:20410263; http://dx.doi.org/10.1128/
JVI.00519-10
18. Boon AC, de Mutsert G, van Baarle D, Smith DJ,
Lapedes AS, Fouchier RA, et al. Recognition of homoand heterosubtypic variants of influenza A viruses
by human CD8+ T lymphocytes. J Immunol 2004;
172:2453-60; PMID:14764717
19. Kreijtz JH, Bodewes R, van Amerongen G, Kuiken
T, Fouchier RA, Osterhaus AD, et al. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 2007; 25:612-20;
PMID:17005299; http://dx.doi.org/10.1016/j.vaccine.2006.08.036

Human Vaccines & Immunotherapeutics

20. Ge X, Tan V, Bollyky PL, Standifer NE, James EA,
Kwok WW. Assessment of seasonal influenza A virusspecific CD4 T-cell responses to 2009 pandemic H1N1
swine-origin influenza A virus. J Virol 2010; 84:33129; PMID:20071564; http://dx.doi.org/10.1128/
JVI.02226-09
21. Ellebedy AH, Ducatez MF, Duan S, Stigger-Rosser E,
Rubrum AM, Govorkova EA, et al. Impact of prior
seasonal influenza vaccination and infection on pandemic A (H1N1) influenza virus replication in ferrets.
Vaccine 2011; 29:3335-9; PMID:20840835; http://
dx.doi.org/10.1016/j.vaccine.2010.08.067
22. Garcia-Garcia L, Valdespino-Gómez JL, LazcanoPonce E, Jimenez-Corona A, Higuera-Iglesias A, CruzHervert P, et al. Partial protection of seasonal trivalent
inactivated vaccine against novel pandemic influenza A/
H1N1 2009: case-control study in Mexico City. BMJ
2009; 339:b3928; PMID:19808768; http://dx.doi.
org/10.1136/bmj.b3928
23. Powell TJ, Peng Y, Berthoud TK, Blais ME, Lillie PJ,
Hill AV, et al. Examination of influenza specific T
cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine. PLoS
One 2013; 8:e62778; PMID:23658773; http://dx.doi.
org/10.1371/journal.pone.0062778
24. Kamperschroer C, Dibble JP, Meents DL, Schwartzberg
PL, Swain SL. SAP is required for Th cell function
and for immunity to influenza. J Immunol 2006;
177:5317-27; PMID:17015717
25. Belz GT, Wodarz D, Diaz G, Nowak MA, Doherty
PC. Compromised influenza virus-specific CD8(+)-Tcell memory in CD4(+)-T-cell-deficient mice. J Virol
2002; 76:12388-93; PMID:12414983; http://dx.doi.
org/10.1128/JVI.76.23.12388-12393.2002
26. Cardin RD, Brooks JW, Sarawar SR, Doherty PC.
Progressive loss of CD8+ T cell-mediated control of a
gamma-herpesvirus in the absence of CD4+ T cells. J
Exp Med 1996; 184:863-71; PMID:9064346; http://
dx.doi.org/10.1084/jem.184.3.863
27. Brooks JW, Hamilton-Easton AM, Christensen JP,
Cardin RD, Hardy CL, Doherty PC. Requirement
for CD40 ligand, CD4(+) T cells, and B cells in an
infectious mononucleosis-like syndrome. J Virol 1999;
73:9650-4; PMID:10516078
28. Marshall D, Sealy R, Sangster M, Coleclough C.
TH cells primed during influenza virus infection
provide help for qualitatively distinct antibody responses to subsequent immunization. J Immunol 1999;
163:4673-82; PMID:10528164
29. Lee LY, Ha LA, Simmons C, de Jong MD, Chau NV,
Schumacher R, et al. Memory T cells established by
seasonal human influenza A infection cross-react with
avian influenza A (H5N1) in healthy individuals. J Clin
Invest 2008; 118:3478-90; PMID:18802496
30. Townsend AR, Skehel JJ. The influenza A virus nucleoprotein gene controls the induction of both subtype
specific and cross-reactive cytotoxic T cells. J Exp Med
1984; 160:552-63; PMID:6206181; http://dx.doi.
org/10.1084/jem.160.2.552

Volume 9 Issue 7

©2013 Landes Bioscience. Do not distribute.

Raw spot counts were recorded by ZellNet Consulting, Inc.
using a Zeiss high-resolution automated ELISpot reader system
and companion KS ELISpot software. Results were calculated as
the average number of spots in the peptide wells, adjusted to spots
per one million cells. A response was considered peptide-specific
if the number of spots was at least twice background, greater than
50 spot forming cells per well (1 response per 20,000 PBMCs),
and statistically different (p < 0.05) from that of the control wells
by the Student’s t-test.

www.landesbioscience.com

37. Elfaki ME, Khalil EA, Degroot AS, Musa AM,
Gutiérrez Núñez A, Younis BM, et al. Immunogenicity
and immune modulatory effects of in silico predicted
L. donovani candidate peptide vaccines. Hum Vaccin
Immunother 2012; 8:1769-74; PMID:22922767;
http://dx.doi.org/10.4161/hv.21881
38. Poland GA. Vaccines against Lyme disease: What happened and what lessons can we learn? Clin Infect Dis
2011; 52(Suppl 3):s253-8; PMID:21217172; http://
dx.doi.org/10.1093/cid/ciq116
39. Squires RB, Noronha J, Hunt V, García-Sastre A,
Macken C, Baumgarth N, et al. Influenza research
database: an integrated bioinformatics resource for
influenza research and surveillance. Influenza Other
Respi Viruses 2012; 6:404-16; PMID:22260278;
http://dx.doi.org/10.1111/j.1750-2659.2011.00331.x
40. De Groot AS, Jesdale BM, Szu E, Schafer JR, Chicz
RM, Deocampo G. An interactive Web site providing
major histocompatibility ligand predictions: application to HIV research. AIDS Res Hum Retroviruses
1997; 13:529-31; PMID:9135870; http://dx.doi.
org/10.1089/aid.1997.13.529
41. Southwood S, Sidney J, Kondo A, del Guercio MF,
Appella E, Hoffman S, et al. Several common HLA-DR
types share largely overlapping peptide binding repertoires. J Immunol 1998; 160:3363-73; PMID:9531296

Human Vaccines & Immunotherapeutics

42. Peterson J, Garges S, Giovanni M, McInnes P, Wang
L, Schloss JA, et al.; NIH HMP Working Group.
The NIH Human Microbiome Project. Genome Res
2009; 19:2317-23; PMID:19819907; http://dx.doi.
org/10.1101/gr.096651.109
43. Chain PS, Grafham DV, Fulton RS, Fitzgerald MG,
Hostetler J, Muzny D, et al.; Genomic Standards
Consortium Human Microbiome Project Jumpstart
Consortium. Genomics. Genome project standards
in a new era of sequencing. Science 2009; 326:2367; PMID:19815760; http://dx.doi.org/10.1126/science.1180614
44. Nelson KE, Weinstock GM, Highlander SK, Worley
KC, Creasy HH, Wortman JR, et al.; Human
Microbiome Jumpstart Reference Strains Consortium.
A catalog of reference genomes from the human microbiome. Science 2010; 328:994-9; PMID:20489017;
http://dx.doi.org/10.1126/science.1183605
45. Steere AC, Klitz W, Drouin EE, Falk BA, Kwok
WW, Nepom GT, et al. Antibiotic-refractory Lyme
arthritis is associated with HLA-DR molecules that
bind a Borrelia burgdorferi peptide. J Exp Med
2006; 203:961-71; PMID:16585267; http://dx.doi.
org/10.1084/jem.20052471

1607

©2013 Landes Bioscience. Do not distribute.

Downloaded by [72.215.236.254] at 12:07 08 October 2015

31. Assarsson E, Bui HH, Sidney J, Zhang Q, Glenn J,
Oseroff C, et al. Immunomic analysis of the repertoire
of T-cell specificities for influenza A virus in humans.
J Virol 2008; 82:12241-51; PMID:18842709; http://
dx.doi.org/10.1128/JVI.01563-08
32. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y,
Kleppinger A, et al. T cell responses are better correlates
of vaccine protection in the elderly. J Immunol 2006;
176:6333-9; PMID:16670345
33. Levitz L, Koita OA, Sangare K, Ardito MT, Boyle CM,
Rozehnal J, et al. Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic
HLA-A2 epitopes selected for the GAIA HIV vaccine.
Vaccine 2012; 30:7547-60; PMID:23102976; http://
dx.doi.org/10.1016/j.vaccine.2012.10.042
34. De Groot AS, Levitz L, Ardito MT, Skowron G,
Mayer KH, Buus S, et al. Further progress on defining highly conserved immunogenic epitopes for a
global HIV vaccine: HLA-A3-restricted GAIA vaccine
epitopes. Hum Vaccin Immunother 2012; 8:9871000; PMID:22777092; http://dx.doi.org/10.4161/
hv.20528
35. De Groot AS, Rivera DS, McMurry JA, Buus S, Martin
W. Identification of immunogenic HLA-B7 “Achilles’
heel” epitopes within highly conserved regions of HIV.
Vaccine 2008; 26:3059-71; PMID:18206276; http://
dx.doi.org/10.1016/j.vaccine.2007.12.004
36. De Groot AS, Ardito M, Terry F, Levitz L, Ross TM,
Moise L, et al. Low immunogenicity predicted for
emerging avian-origin H7N9: Implication for influenza
vaccine design. Hum Vaccin Immunother 2013; 9: In
press; PMID:23807079; http://dx.doi.org/10.4161/
hv.24939.

